## Direct vs Indirect Pathway: Functional Distinction ### Pathway Architecture **Key Point:** Both pathways are fundamentally GABAergic (inhibitory) in their output to the thalamus, but they achieve opposite functional outcomes through different circuit configurations. ### Direct Pathway (Movement Facilitation) 1. Cortex → Striatum (D1-receptor neurons) → GPi/SNr → Thalamus 2. **Net effect:** Inhibition of GPi/SNr → **Disinhibition of thalamus** → Movement facilitation 3. Dopamine (D1 agonism) **enhances** this pathway ### Indirect Pathway (Movement Inhibition) 1. Cortex → Striatum (D2-receptor neurons) → GPe → STN → GPi/SNr → Thalamus 2. **Net effect:** Reduced inhibition of GPi/SNr → **Increased inhibition of thalamus** → Movement suppression 3. Dopamine (D2 antagonism) **reduces** this pathway ### Comparison Table | Feature | Direct Pathway | Indirect Pathway | |---------|---|---| | **Striatal neuron type** | D1-receptor neurons | D2-receptor neurons | | **Neurotransmitter** | GABA (both pathways) | GABA (both pathways) | | **GPi/SNr output** | Decreased inhibition | Increased inhibition | | **Thalamic effect** | Disinhibition → activation | Inhibition → suppression | | **Functional role** | Facilitates intended movement | Suppresses unwanted movement | | **Dopamine effect** | Enhances (D1 agonism) | Reduces (D2 antagonism) | **High-Yield:** The **functional outcome** (disinhibition vs. inhibition) is the best discriminator, not the neurotransmitter type (both use GABA). ### Clinical Correlate **Clinical Pearl:** In Parkinson's disease (dopamine loss), the indirect pathway becomes overactive relative to the direct pathway, resulting in: - Excessive thalamic inhibition - Bradykinesia and rigidity - Tremor at rest This explains why dopaminergic agents (L-DOPA) and D1 agonists restore balance by re-enhancing the direct pathway. [cite:Kandel Principles of Neural Science 6e Ch 41] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.